---
document_datetime: 2023-09-21 18:53:39
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/tachosil-epar-procedural-steps-taken-authorisation_en.pdf
document_name: tachosil-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.3667575
conversion_datetime: 2025-12-25 10:48:11.180897
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The  applicant  Nycomed  Austria  GmbH  submitted  on    4  July  2002  an  application  for  Marketing Authorisation  to  the  European  Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA)  for TachoSil, in accordance with the centralised procedure falling within the scope of Part B of the Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993, as amended.

The Rapporteur and Co-Rapporteur appointed by the CPMP were: Rapporteur: Dr. Manfred Haase Co-Rapporteur:

## 2. Steps taken for the assessment of the product

- The procedure started on 22 July 2002.
- The Rapporteur's first Assessment Report was circulated to all CPMP  members on 30 September 2002 . The Co-Rapporteur's first Assessment Report was circulated to all CPMP members on 10 September 2002.
- During  the  meeting  on  19  November  2002,  the  CPMP  agreed  on  the  consolidated  List  of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on  21 November 2002.
- The  applicant  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on  14 October 2003.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CPMP members on  24 November 2003.
- During the CPMP meeting on 18 December 2003, the CPMP agreed on a list of outstanding issues to be addressed in writing by the applicant.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of outstanding issues to all CPMP members on 3 February 2004.
- During  the  meeting  on    24-26  February  2004,  the  CPMP,  in  the  light  of  the  overall  data submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for granting a Marketing Authorisation to TachoSil on 26 February 2004. The applicant provided the  letter  of  undertaking  on  the  follow-up  measures  to  be  fulfilled  post-authorisation  on  26 February 2004.

Dr. Ian Hudson